Biotech firms lobby Trump to exempt rare disease drugs from Medicare price cuts

The Rare Disease Company Coalition met with the White House Office of Management and Budget to seek an exemption from two Medicare pilot programmes designed to bring US drug prices in line with those in other wealthy nations — a policy known as most-favoured nation pricing. Biotech firms argue that applying price cuts to orphan drugs would undermine investment in rare disease research. The meeting is part of broader industry lobbying against Trump's drug pricing plan.

Should rare disease drugs be exempt from Medicare drug price-cut programmes?

STAT News · 8d ago · Source ↗

Comments

No comments yet

🔥 Hot right now

Biotech firms lobby Trump to exempt rare disease drugs from Medicare price cuts

Comments

Comments

You're all caught up

Scroll like on TikTok